Skip to main content

Research Repository

Advanced Search

New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline

Corsetti, Maura; Whorwell, Peter

Authors

MAURA CORSETTI Maura.Corsetti@nottingham.ac.uk
Clinical Associate Professor

Peter Whorwell



Abstract

Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a major cost to healthcare services. IBS-D patients represent about one-third of the IBS population and are currently treated with antispasmodics, loperamide, bile acid sequestrants and antidepressants. Alosetron and rifaximin are also available in USA, ramosetron in Japan, Korea and Thailand and ondansetron as an off-label treatment.

Areas covered: This article focuses on eluxadoline, a novel pharmacological agent that has recently been approved by both the FDA and EMA for treatment of patients with IBS-D.

Expert commentary: The efficacy and safety of eluxadoline in treating bowel habit alterations and pain, both in the short and long-term, make the drug a welcome addition to our therapeutic alternatives in IBS-D. Its positioning in any IBS algorithm will depend on the ‘real world’ prevalence of the small risk of sphincter of Oddi spasm and mild pancreatitis.

Citation

Corsetti, M., & Whorwell, P. (2017). New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline. Expert Review of Gastroenterology and Hepatology, 11(4), 285-292. https://doi.org/10.1080/17474124.2017.1298442

Journal Article Type Article
Acceptance Date Feb 20, 2017
Online Publication Date Mar 1, 2017
Publication Date Apr 3, 2017
Deposit Date Dec 21, 2018
Journal Expert Review of Gastroenterology & Hepatology
Print ISSN 1747-4124
Electronic ISSN 1747-4132
Publisher Taylor & Francis
Peer Reviewed Peer Reviewed
Volume 11
Issue 4
Pages 285-292
DOI https://doi.org/10.1080/17474124.2017.1298442
Public URL https://nottingham-repository.worktribe.com/output/1438370
Additional Information Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.; Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierh20